



Cellino Intro

Nabiha Saklayen, PhD

Co-Founder & CEO

nsaklayen@cellinobio.com

cellino



cellino

EVERY HUMAN.
EVERY CELL.


Autologous Cell Therapies at Scale

Mission

Build the leading platform for precision manufacturing of regenerative therapies

Vision

Unlock regenerative medicine for hundreds of millions of patients




*exact locations will depend on cell type and partner needs

Cellino's Proprietary Engine Industrializes Artisanal Processes



AUTOMATE



SCALE



Target 2025




An Optical Approach to Cell Engineering is Precise and Scalable



Imaging + Analysis - Proprietary




Laser Editing - Proprietary



We Use Multimodal Datasets to Enhance Human Decisions


Cellino-owned infrastructure and algorithms




Automated Workcell




Imaging




Sequencing




Karyotyping



Flow Cytometry



Platform Designed to Deliver Cell Products Near Patients



First Clinical Products on Platform

Product	Disease	Global Patient Population	Clinical Collaborator
iPSC – induced Pluripotent Stem Cells	Starting material for most regenerative therapies	--	NIH
RPE – Retinal Pigment Epithelial Cells	Age-related Macular Degeneration	288M	NIH
DOPA – Dopaminergic Neurons	Parkinson's	7M	TBD